Sunday, April 30, 2023, Chicago, Illinois, 6:00 PM – 8:00 PM Central Time (7:00 PM – 9:00 PM Eastern Time)

Beyond The Guidelines: Urologic Oncology Investigators Provide Perspectives on the Optimal Management of Prostate Cancer

A CME Satellite Symposium in Conjunction with the American Urological Association Annual Meeting 2023 (AUA2023)

Location
McCormick Place Convention Center
2301 South Martin Luther King Drive
Chicago, IL 60616
Phone: (312) 791-7000

Program Schedule — Central Time
5:30 PM – 6:00 PM — Registration
6:00 PM – 8:00 PM — Dinner Meeting

Meeting Room
Grand Ballroom (S100) – Level 1, South Building


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.  
 
Faculty
Stephen J Freedland, MD
Staff Physician, Durham VA Medical Center
Durham, North Carolina
Professor of Urology
Warschaw, Robertson, Law Families Chair
in Prostate Cancer
Director, Center for Integrated Research on Cancer and Lifestyle (CIRCL)
Associate Director for Education and Training
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, California

Fred Saad, MD
Professor and Chief of Urology
Director of GU Oncology
Raymond Garneau Chair in Prostate Cancer
University of Montreal Hospital Center (CHUM)
Director, Prostate Cancer Research
Montreal Cancer Institute/CRCHUM
Montréal, Québec, Canada


Neal D Shore, MD
Director, CPI
Carolina Urologic Research Center
Chief Medical Officer, Surgery/Urology
GenesisCare
Medical Director, CUSP: Clinical Research Consortium
Myrtle Beach, South Carolina

Matthew R Smith, MD, PhD
Claire and John Bertucci Endowed Chair in Genitourinary Cancers
Professor of Medicine
Harvard Medical School
Director, Genitourinary Malignancies Program
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Moderator
To be announced.


This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Lilly, and Merck.
Program Schedule — Central Time
5:30 PM – 6:00 PM — Registration
6:00 PM – 8:00 PM — Educational Dinner Meeting

MODULE 1: Management Approaches for Nonmetastatic Prostate Cancer

  • Indications for and selection of androgen deprivation therapy (ADT) for patients with prostate cancer
  • Key efficacy and safety data with and FDA-approved indications for relugolix; optimal integration into practice
  • Findings from the STAMPEDE trial of abiraterone and prednisolone with or without enzalutamide in combination with ADT for men with high-risk nonmetastatic prostate cancer; current clinical implications
  • Major efficacy and safety results and practical implications of the Phase III PRESTO study evaluating ADT intensification with apalutamide with or without abiraterone for patients with biochemically recurrent prostate cancer and a rapid PSA doubling time
  • Other ongoing Phase III trials evaluating secondary hormonal agents for high-risk localized or locally advanced prostate cancer
  • Long-term efficacy and safety outcomes with apalutamide, enzalutamide or darolutamide for patients with nonmetastatic castration-resistant prostate cancer (CRPC)
  • Clinical, biologic and practical factors in the selection of enzalutamide, apalutamide or darolutamide for patients with nonmetastatic CRPC

MODULE 2: : Optimizing the Care of Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

  • Key clinical, biologic and practical factors in the selection of systemic therapy for patients with mHSPC
  • Long-term efficacy and safety data, including overall survival findings, with docetaxel, abiraterone, enzalutamide and apalutamide, each in combination with ADT, for mHSPC
  • Major findings from the Phase III PEACE-1 study of ADT with or without docetaxel, with or without local radiation therapy, with or without abiraterone and prednisone for mHSPC
  • Published efficacy and safety results from the Phase III ARASENS trial of darolutamide in combination with docetaxel and ADT for mHSPC; FDA-approved indication and optimal incorporation into management algorithms
  • Outcomes observed in the subset of patients who received docetaxel in addition to enzalutamide and ADT in the Phase III ENZAMET study
  • Ongoing Phase III trials attempting to further define the optimal management of mHSPC (eg, TALAPRO-3, CYCLONE 3, PSMAddition)

MODULE 3: Therapeutic Considerations for Patients with Newly Diagnosed Metastatic CRPC (mCRPC)

  • Key clinical and biologic factors in the selection of therapy for patients with newly diagnosed mCRPC; impact of earlier use of chemotherapy and secondary hormonal therapy on current treatment algorithms
  • Key findings from clinical trial and real-world data sets exploring the efficacy and safety of sipuleucel-T for mCRPC; effect on outcomes of patient age, race, PSA level and other factors
  • Optimal patient selection for treatment with sipuleucel-T; importance of early identification of appropriate candidates
  • Biologic basis for combining PARP inhibitors with antiandrogen therapies for prostate cancer; rationale for the activity of these combinations as front-line therapy in patients without HRR gene mutations
  • Available and emerging data with PARP inhibitors combined with secondary hormonal agents for previously untreated mCRPC (eg, from the PROpel, MAGNITUDE and TALAPRO-2 trials)
  • Other ongoing Phase III studies evaluating PARP inhibitors in combination with androgen receptor (AR)-targeted agents for mCRPC and mHSPC
  • Biologic rationale for the evaluation of CDK4/6 inhibitors in patients with mCRPC
  • Design, eligibility criteria and primary and secondary endpoints of the Phase II/III CYCLONE 2 trial evaluating first-line abiraterone and prednisone with or without abemaciclib for mCRPC; estimated study completion date

MODULE 4: Contemporary Management of mCRPC in Patients Harboring an HRR Gene Alteration

  • Incidence and clinical implications of BRCA1/2 and other HRR abnormalities (eg, ATM, PALB2, CDK12) in patients with prostate cancer
  • Mechanistic similarities and differences between approved (eg, olaparib, rucaparib) and investigational (eg, talazoparib, niraparib) PARP inhibitors with documented activity in patients with mCRPC; implications for activity and tolerability
  • Available data with PARP inhibitor monotherapy for patients with mCRPC (eg, from the PROfound, TRITON2, TRITON3, GALAHAD and TALAPRO-1 trials)
  • FDA-approved indications for olaparib and rucaparib for mCRPC and optimal integration into management algorithms
  • Key findings from the Phase III PROpel and MAGNITUDE trials for patients with HRR gene alterations; ramifications for current and future practice
  • Implications of emerging findings from TALAPRO-2 for the management of mCRPC in patients with HRR gene mutations

MODULE 5: Current and Emerging Strategies in the Treatment of Recurrent mCRPC

  • Available data with, ongoing evaluation of and patient selection for treatment with radium-223 chloride
  • Clinical relevance of PSMA expression in prostate cancer; mechanism of action of the novel radioligand 177Lu-PSMA-617
  • Key efficacy and safety findings from the Phase III VISION study evaluating 177Lu-PSMA-617 for patients with progressive PSMA-positive mCRPC; FDA approval and optimal incorporation into management algorithms
  • Design, eligibility criteria and emerging findings from the Phase III PSMAfore trial comparing 177Lu-PSMA-617 to a change in AR-directed therapy for patients with mCRPC previously treated with an alternate AR pathway inhibitor but not exposed to taxane-containing chemotherapy; implications for therapeutic sequencing
  • Spectrum, frequency and management of toxicities associated with 177Lu-PSMA-617
  • Major efficacy and safety findings from the CARD study and other recently reported trials (eg, OSTRICh, CABASTY) investigating cabazitaxel for mCRPC
  • Appropriate integration of cabazitaxel into current mCRPC treatment algorithms and practical considerations for its use
  • Clinical activity of cabozantinib in patients with mCRPC; preliminary findings from the mCRPC cohort of the Phase Ib COSMIC-021 trial evaluating cabozantinib in combination with atezolizumab
  • Design, eligibility criteria and key efficacy and safety endpoints of the Phase III CONTACT-02 trial examining the role of cabozantinib/atezolizumab in therapy for mCRPC
  • Other promising novel agents and strategies under investigation for mCRPC

Target Audience
This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of prostate cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Appraise published research findings and current guideline recommendations on optimal management approaches for biochemical recurrence after local treatment for prostate cancer, and appropriately counsel patients about the potential benefits of systemic therapy.
  • Evaluate the research database supporting the FDA approvals of secondary hormonal agents in the management of nonmetastatic castration-resistant prostate cancer (CRPC), and apply this information in presenting nonresearch treatment options to patients.
  • Explore available data with treatment intensification using cytotoxic therapy, secondary hormonal therapy or combinations of these approaches for metastatic hormone-sensitive prostate cancer, and effectively integrate these strategies into clinical management algorithms.
  • Establish an evidence-based approach to the selection and sequencing of therapies for patients with metastatic CRPC (mCRPC), considering age, comorbidities, prior therapeutic exposure and other clinical and biologic factors.
  • Assess the research database supporting the use of PARP inhibitors as monotherapy for patients with mCRPC harboring a homologous recombination repair (HRR) gene alteration, and discern how to optimally incorporate these agents into clinical management algorithms.
  • Develop an understanding of the rationale for, available and emerging data with and ongoing research evaluating PARP inhibitors in combination with androgen receptor-targeted therapy, and consider the potential role of these novel regimens in therapy for patients both with and without HRR gene mutations.
  • Appreciate Phase III data documenting the efficacy of PSMA-targeted radioligand therapy in patients with progressive PSMA-positive mCRPC, and consider the current clinical role of this strategy.
  • Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and appropriately counsel patients about availability and participation.

CME Credit Form
A CME credit link will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be provided.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Lilly, and Merck.

McCormick Place Convention Center
2301 South Martin Luther King Drive
Chicago, IL 60616
Phone: (312) 791-7000

Meeting Room
Grand Ballroom (S100) – Level 1, South Building

Directions
The McCormick Place Convention Center is the main venue for the 2023 AUA Annual Meeting.

 
This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of prostate cancer.

There is no fee to participate in this hybrid event. For the in-person symposium in Chicago preregistration is required as seating is limited.
​ ​
IN-PERSON registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

In-person Registration for clinicians in practice »
 
IN-PERSON registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

In-person Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST registration for all professionals

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.